Reviews

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the “Undruggable” Paradigm

Volume 37 · Issue 4 Publish Date: January 30, 2026
Full Text PDF
DOI
Wenyu Li ORCID
Department of Hepato-Biliary-Pancreatic Surgery, People’s Hospital of Henan University/Zhengzhou University People’s Hospital, Zhengzhou, China
Xiang Lin ORCID
Department of Hepato-Biliary-Pancreatic Surgery, People’s Hospital of Henan University/Zhengzhou University People’s Hospital, Zhengzhou, China
Pan Liu ORCID
Department of Hepato-Biliary-Pancreatic Surgery, People’s Hospital of Henan University/Zhengzhou University People’s Hospital, Zhengzhou, China
Jing Zhang ORCID
Department of Hepato-Biliary-Pancreatic Surgery, People’s Hospital of Henan University/Zhengzhou University People’s Hospital, Zhengzhou, China
Chuanjiang Liu ORCID
Department of Hepato-Biliary-Pancreatic Surgery, People’s Hospital of Henan University/Zhengzhou University People’s Hospital, Zhengzhou, China
Li, W., Lin, X., Liu, P., Zhang, J., & Liu, C. (2026). Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the “Undruggable” Paradigm. Turkish Journal of Gastroenterology, 37(4), 409–419. https://doi.org/10.5152/tjg.2026.25595
Full Text Full Text PDF

Abstract

Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal malignancies, exhibits a 5-year survival rate below 10% and extremely poor clinical prognosis. Over 90% of PDAC patients harbor KRAS gene driver mutations, which promote tumor proliferation, invasion, and immunosuppression of the tumor microenvironment through constitutive activation of downstream RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways. Although the therapeutic potential of targeting KRAS has been recognized for decades, its smooth protein structure and lack of traditional drug-binding pockets led to its long-standing classification as an “undruggable” target, resulting in limited efficacy of early targeted agents. Recent breakthroughs with next-generation KRAS inhibitors have transformed the therapeutic landscape for pancreatic cancer. This review synthesizes evidence from basic research and clinical translation to provide a theoretical foundation and practical guidance for the precision treatment of KRAS-mutant pancreatic cancer.

Cite this article as: Li W, Lin X, Liu P, et al. Emerging therapeutic landscapes for KRAS-mutant pancreatic ductal adenocarcinoma: beyond the “undruggable” paradigm. Turk J Gastroenterol. Published online January 30, 2026. doi: 10.5152/tjg.2026.25595

Article Info
Published In
Journal Turkish Journal of Gastroenterology
Volume / Issue Volume 37 · Issue 4
Pages 409-419
History
Published Online January 30, 2026
License
Copyright
Affiliations
Wenyu Li ORCID
Department of Hepato-Biliary-Pancreatic Surgery, People’s Hospital of Henan University/Zhengzhou University People’s Hospital, Zhengzhou, China
Xiang Lin ORCID
Department of Hepato-Biliary-Pancreatic Surgery, People’s Hospital of Henan University/Zhengzhou University People’s Hospital, Zhengzhou, China
Pan Liu ORCID
Department of Hepato-Biliary-Pancreatic Surgery, People’s Hospital of Henan University/Zhengzhou University People’s Hospital, Zhengzhou, China
Jing Zhang ORCID
Department of Hepato-Biliary-Pancreatic Surgery, People’s Hospital of Henan University/Zhengzhou University People’s Hospital, Zhengzhou, China
Chuanjiang Liu ORCID
Department of Hepato-Biliary-Pancreatic Surgery, People’s Hospital of Henan University/Zhengzhou University People’s Hospital, Zhengzhou, China
Cite this Article
Li, W., Lin, X., Liu, P., Zhang, J., & Liu, C. (2026). Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the “Undruggable” Paradigm. Turkish Journal of Gastroenterology, 37(4), 409–419. https://doi.org/10.5152/tjg.2026.25595
Outlines